Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence
| Autor: | David Bakhshinyan, Ashley A. Adile, Jeff Liu, William D. Gwynne, Yujin Suk, Stefan Custers, Ian Burns, Mohini Singh, Nicole McFarlane, Minomi K. Subapanditha, Maleeha A. Qazi, Parvez Vora, Michelle M. Kameda-Smith, Neil Savage, Kim L. Desmond, Nazanin Tatari, Damian Tran, Mathieu Seyfrid, Kristin Hope, Nicholas A. Bock, Chitra Venugopal, Gary D. Bader, Sheila K. Singh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Science Advances |
| ISSN: | 2375-2548 |
| Popis: | Description Gene expression profiling of medulloblastoma cells undergoing therapy identifies BPIFB4 as a novel target for recurrent disease. Medulloblastoma (MB) remains a leading cause of cancer-related mortality among children. The paucity of MB samples collected at relapse has hindered the functional understanding of molecular mechanisms driving therapy failure. New models capable of accurately recapitulating tumor progression in response to conventional therapeutic interventions are urgently needed. In this study, we developed a therapy-adapted PDX MB model that has a distinct advantage of generating human MB recurrence. The comparative gene expression analysis of MB cells collected throughout therapy led to identification of genes specifically up-regulated after therapy, including one previously undescribed in the setting of brain tumors, bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4). Subsequent functional validation resulted in a markedly diminished in vitro proliferation, self-renewal, and longevity of MB cells, translating into extended survival and reduced tumor burden in vivo. Targeting endothelial nitric oxide synthase, a downstream substrate of BPIFB4, impeded growth of several patient-derived MB lines at low nanomolar concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|